Skip to content

Tumour Sites
- Breast
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Career Hub
- View Openings
- Post A Job
About Us
My Account
Search

Tumour Sites
- Breast
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Career Hub
- View Openings
- Post A Job
About Us
My Account
Search

Login
Register
My Account
- Edit Profile
search

Login
Register
My Account
- Edit Profile
search

Search for:

ASH HIGHLIGHTS 2024 ROUNDTABLE DISCUSSIONS

ASH HIGHLIGHTS 2024 ROUNDTABLE DISCUSSIONS

ASH RT LP png

Videos

LEUKEMIA

Dr. Julie Bergeron (Chair)

Dr. Julie Bergeron

Dr. Lynn Savoie

Dr. Lynn Savoie

Dr. Brett Houston

Dr. Brett Houston

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Menin Inhibitors in AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Ivosidenib with Venetoclax Azacitidine in IDH1-Mutated Hematologic Malignancies

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Venetoclax Plus Azacitidine for Newly Diagnosed Younger AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Alliance A041501 Phase 3 Randomized Trial

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Intermediate Analysis of the Gimema ALL2820

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell ALL

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Phase 2 ASC2ESCALATE Trial

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: TIPI in Front-Line Treatment of CP CML Setting

LYMPHOMA

Dr. Carolyn Owen (Chair)

Dr. Carolyn Owen

Dr. Kerry Savage

Dr. Kerry Savage

Dr. Anca Prica

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Pembro Main instead of auto-SCT in RRcHL

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Bleomycin Omission in PET-Negative HL

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Phase 3 AMPLIFY Trial

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: ECOG-ACRIN EA4151 Phase 3 Randomized Trial

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Triangle Data Embedded in the Multiply Project

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Results from the Randomized Triangle Trial By the European MCL Network

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: First Results from the CIBMTR Registry

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Results from a Phase 3 Study (inMIND)

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Mithic-FL1 Trial

MULTIPLE MYELOMA

Dr. Donna Reece (Chair)

Dr. Donna Reece

Dr. Darrell White

Dr. Darrell White

Dr. Maria-Victoria Mateos

Dr. Maria Victoria Mateos Manteca

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Primary Results of the Aquila Study

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Phase 3 Auriga Study Among Clinically Relevant Subgroups

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Sustained MRD negativity for 3 years can guide discontinuation of len maintenance: Results from a prospective cohort study

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: SRI Results from the Majestec-4/EMN30 Trial

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Results of TEC, POM.Majestec-2 and TRIMM-2 results

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Results of TEC in patients with prior BCMA-directed therapy

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Pre-apheresis prediction of toxicity and response in patients receiving BCMA-directed CAR-T in RRMM

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Stem Cell Boost for ICAHT following BMCA-directed CAR-T cell therapy

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Reevaluating IMWG criteria for CR in the Era of Mass Spectrometry

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Novel Prognostic System Based on Circulating Tumor Cells

Podcasts

LEUKEMIA

Dr. Julie Bergeron (Chair)

Dr. Julie Bergeron

Dr. Lynn Savoie

Dr. Lynn Savoie

Dr. Brett Houston

Dr. Brett Houston

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Menin Inhibitors in AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Ivosidenib with Venetoclax Azacitidine in IDH1-Mutated Hematologic Malignancies

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Venetoclax Plus Azacitidine for Newly Diagnosed Younger AML

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Alliance A041501 Phase 3 Randomized Trial

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Intermediate Analysis of the Gimema ALL2820

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell ALL

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: Phase 2 ASC2ESCALATE Trial

2024

ASH HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSIONS: TIPI in Front-Line Treatment of CP CML Setting

LYMPHOMA

Dr. Carolyn Owen (Chair)

Dr. Carolyn Owen

Dr. Kerry Savage

Dr. Kerry Savage

Dr. Anca Prica

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Pembro Main instead of auto-SCT in RRcHL

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Bleomycin Omission in PET-Negative HL

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Phase 3 AMPLIFY Trial

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: ECOG-ACRIN EA4151 Phase 3 Randomized Trial

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Triangle Data Embedded in the Multiply Project

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Results from the Randomized Triangle Trial By the European MCL Network

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: First Results from the CIBMTR Registry

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Results from a Phase 3 Study (inMIND)

2024

ASH HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSIONS: Mithic-FL1 Trial

MULTIPLE MYELOMA

Dr. Donna Reece (Chair)

Dr. Donna Reece

Dr. Darrell White

Dr. Darrell White

Dr. Maria-Victoria Mateos

Dr. Maria Victoria Mateos Manteca

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Primary Results of the Aquila Study

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Phase 3 Auriga Study Among Clinically Relevant Subgroups

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Sustained MRD negativity for 3 years can guide discontinuation of len maintenance: Results from a prospective cohort study

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: SRI Results from the Majestec-4/EMN30 Trial

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Results of TEC, POM.Majestec-2 and TRIMM-2 results

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Results of TEC in patients with prior BCMA-directed therapy

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Pre-apheresis prediction of toxicity and response in patients receiving BCMA-directed CAR-T in RRMM

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Stem Cell Boost for ICAHT following BMCA-directed CAR-T cell therapy

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Reevaluating IMWG criteria for CR in the Era of Mass Spectrometry

2024

ASH HIGHLIGHTS 2024 – MULTIPLE MYELOMA ROUNDTABLE DISCUSSIONS: Novel Prognostic System Based on Circulating Tumor Cells

To Top

Tagged page-parent-for-videos-or-podcasts

© All rights reserved

Made with ❤ by Elementor

Oncology Career Hub
Post A Job
Scientific Steering Committee
Events
Podcast

About Us
Contact Us
Disclaimer
MDBriefCase

199 Bay Street #4000
Toronto, ON M5L 1A9

©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.

Twitter Instagram Facebook-f Linkedin-in

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Tumour Sites
- Breast
- Colorectal
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Oncology Career Hub
- View Openings
- Post A Job
About Us

Login
Register

Search for:

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. See our privacy policy and cookie policy.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!